Palo Alto, CA, United States of America

Maureen A McNally


Average Co-Inventor Count = 3.0

ph-index = 6

Forward Citations = 491(Granted Patents)


Company Filing History:


Years Active: 1992-1998

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Maureen A McNally: A Pioneer in Recombinant Adeno-Associated Virus Technology

Introduction

Maureen A McNally is an accomplished inventor based in Palo Alto, California, known for her significant contributions to biotechnology, particularly in the field of recombinant adeno-associated viruses (rAAV). With a total of six patents to her name, McNally's work has advanced methods to produce viral vectors essential for gene therapy and other applications.

Latest Patents

Among her notable patents are innovative methods for producing recombinant adeno-associated virus vectors. These inventions describe simplified techniques using chimeric plasmids that incorporate the Epstein Barr nuclear antigen (EBNA) gene and the latent origin of replication of the Epstein Barr virus (oriP) along with a rAAV genome. The chimeric plasmids are designed to be maintained as multicopy extra-chromosomal elements, particularly in human 293 cells. When induced with wild-type adeno-associated virus helper functions, these permanent cell lines can produce large amounts of rAAV, which are capable of transducing exogenous genes into human cell lines.

Career Highlights

Throughout her career, McNally has made significant strides in the biotechnology sector. She has worked with various prestigious companies, including Applied Immunesciences, Inc. and Rhone-Poulenc Rorer Pharmaceuticals Inc. Her research and inventions have had a lasting impact and continue to be integral in the field of gene therapy.

Collaborations

Collaborating with prominent figures in the field, McNally has worked alongside respected professionals such as Jane S Lebkowski and Thomas B Okarma. These partnerships have further enriched her research and contributed to her innovative findings.

Conclusion

Maureen A McNally's pioneering work in recombinant adeno-associated virus technology has positioned her as a leading inventor in biotechnology. Her patents continue to shape the landscape of gene therapy, demonstrating the importance of innovations in enhancing therapeutic methods and clinical outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…